-
Chong
Sun,
R.
Mezzadra,
T.
Schumacher
(2018)
Regulation and Function of the PD-L1 Checkpoint.
Immunity, 48 3
-
J.
Bellmunt,
R.
Wit,
D.
Vaughn,
Y.
Fradet,
Jae-Lyun
Lee,
L.
Fong,
N.
Vogelzang,
M.
Climent,
D.
Petrylak,
T.
Choueiri,
A.
Necchi,
W.
Gerritsen,
H.
Gurney,
D.
Quinn,
S.
Culine,
C.
Sternberg,
Yabing
Mai,
C.
Poehlein,
R.
Perini,
D.
Bajorin
(2017)
Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma
The New England Journal of Medicine, 376
-
R.
Herbst,
P.
Baas,
Dong-Wan
Kim,
E.
Felip,
J.
Pérez-Gracia,
Ji-Youn
Han,
J.
Molina,
Joo‐Hang
Kim,
C.
Arvis,
M.
Ahn,
M.
Majem,
M.
Fidler,
G.
Castro,
M.
Garrido,
G.
Lubiniecki,
Shentu
Yue,
E.
Im,
M.
Dolled-Filhart,
E.
Garon
(2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
The Lancet, 387
-
J.
Higgins,
D.
Altman,
P.
Gøtzsche,
P.
Jüni,
D.
Moher,
A.
Oxman,
J.
Savović,
K.
Schulz,
L.
Weeks,
J.
Sterne
(2011)
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
The BMJ, 343
-
J.
Wetterslev,
K.
Thorlund,
J.
Brok,
C.
Gluud
(2008)
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis.
Journal of clinical epidemiology, 61 1
-
(2015)
CXCR4 overexpression and survival in cancer: a system review and meta-analysis
-
J.
Larkin,
D.
Minor,
S.
D’Angelo,
B.
Neyns,
M.
Smylie,
W.
Miller,
R.
Gutzmer,
G.
Linette,
B.
Chmielowski,
C.
Lao,
P.
Lorigan,
K.
Grossmann,
J.
Hassel,
M.
Sznol,
A.
Daud,
J.
Sosman,
N.
Khushalani,
D.
Schadendorf,
C.
Hoeller,
D.
Walker,
G.
Kong,
C.
Horak,
J.
Weber
(2017)
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 4
-
J.
Brok,
K.
Thorlund,
C.
Gluud,
J.
Wetterslev
(2008)
Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses.
Journal of clinical epidemiology, 61 8
-
M.
Egger,
G.
Smith,
Martin
Schneider,
C.
Minder
(1997)
Bias in meta-analysis detected by a simple, graphical test
BMJ, 315
-
Bin
Zhao,
Hong
Zhao,
Jiaxin
Zhao
(2019)
Risk of fatal adverse events in cancer patients treated with sunitinib.
Critical reviews in oncology/hematology, 137
-
Jason
Lazarou,
B.
Pomeranz,
Paul
Corey
(1998)
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.
JAMA, 279 15
-
Bin
Zhao,
Hong
Zhao
(2018)
Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor‐2‐positive breast cancer
International Journal of Cancer, 142
-
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: nivolumab-related serious/fatal adverse events
-
C.
Robert,
G.
Long,
B.
Brady,
C.
Dutriaux,
M.
Maio,
L.
Mortier,
J.
Hassel,
P.
Rutkowski,
C.
McNeil,
E.
Kalinka‐Warzocha,
K.
Savage,
M.
Hernberg,
C.
Lebbé,
J.
Charles,
C.
Mihalcioiu,
V.
Chiarion-Sileni,
C.
Mauch,
F.
Cognetti,
A.
Arance,
H.
Schmidt,
D.
Schadendorf,
H.
Gogas,
L.
Lundgren-Eriksson,
C.
Horak,
B.
Sharkey,
I.
Waxman,
V.
Atkinson,
P.
Ascierto
(2015)
Nivolumab in previously untreated melanoma without BRAF mutation.
The New England journal of medicine, 372 4
-
Bin
Zhao,
Hong
Zhao,
Jiaxin
Zhao
(2018)
Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma
International Journal of Cancer, 144
-
Robert
Ferris,
G.
Blumenschein,
J.
Fayette,
J.
Guigay,
A.
Colevas,
L.
Licitra,
K.
Harrington,
S.
Kasper,
E.
Vokes,
C.
Even,
F.
Worden,
Nabil
Saba,
L.
Docampo,
R.
Haddad,
T.
Rordorf,
N.
Kiyota,
M.
Tahara,
M.
Monga,
M.
Lynch,
W.
Geese,
J.
Kopit,
James
Shaw,
Maura
Gillison
(2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
The New England journal of medicine, 375 19
-
J.
Brahmer,
K.
Reckamp,
P.
Baas,
L.
Crinò,
W.
Eberhardt,
E.
Poddubskaya,
S.
Antonia,
A.
Płużański,
E.
Vokes,
E.
Holgado,
D.
Waterhouse,
N.
Ready,
J.
Gainor,
O.
Frontera,
L.
Havel,
M.
Steins,
M.
Garassino,
J.
Aerts,
M.
Dómine,
L.
Paz-Ares,
M.
Reck,
C.
Baudelet,
C.
Harbison,
B.
Lestini,
D.
Spigel
(2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
The New England journal of medicine, 373 2
-
A.
Eggermont,
C.
Blank,
M.
Mandalà,
G.
Long,
V.
Atkinson,
S.
Dalle,
A.
Haydon,
M.
Lichinitser,
A.
Khattak,
M.
Carlino,
S.
Sandhu,
J.
Larkin,
S.
Puig,
P.
Ascierto,
P.
Rutkowski,
D.
Schadendorf,
R.
Koornstra,
L.
Hernandez-Aya,
M.
Maio,
A.
Eertwegh,
J.
Grob,
R.
Gutzmer,
R.
Jamal,
P.
Lorigan,
N.
Ibrahim,
S.
Marréaud,
A.
Akkooi,
S.
Suciu,
C.
Robert
(2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
The New England Journal of Medicine, 378
-
A.
Ribas,
J.
Wolchok
(2018)
Cancer immunotherapy using checkpoint blockade
Science, 359
-
J.
Weber,
M.
Mandalà,
M.
Vecchio,
H.
Gogas,
A.
Arance,
L.
Cowey,
S.
Dalle,
M.
Schenker,
V.
Chiarion-Sileni,
I.
Márquez-Rodas,
J.
Grob,
M.
Butler,
M.
Middleton,
M.
Maio,
V.
Atkinson,
P.
Queirolo,
R.
Gonzalez,
R.
Kudchadkar,
M.
Smylie,
N.
Meyer,
L.
Mortier,
M.
Atkins,
G.
Long,
S.
Bhatia,
C.
Lebbé,
P.
Rutkowski,
K.
Yokota,
N.
Yamazaki,
T.
Kim,
V.
Pril,
J.
Sabater,
A.
Qureshi,
J.
Larkin,
P.
Ascierto
(2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
The New England Journal of Medicine, 377
-
T.
Powles,
I.
Durán,
M.
Heijden,
Y.
Loriot,
N.
Vogelzang,
U.
Giorgi,
S.
Oudard,
M.
Retz,
D.
Castellano,
A.
Bamias,
A.
Flechon,
G.
Gravis,
S.
Hussain,
T.
Takano,
N.
Leng,
E.
Kadel,
R.
Banchereau,
P.
Hegde,
S.
Mariathasan,
N.
Cui,
Xiao-dong
Shen,
C.
Derleth,
Marjorie
Green,
A.
Ravaud
(2018)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
The Lancet, 391
-
(2017)
Risk of treatmentrelated mortality in cancer patients treated with ipilimumab: a systematic review and metaanalysis
-
D.
Carbone,
M.
Reck,
L.
Paz-Ares,
B.
Creelan,
L.
Horn,
M.
Steins,
E.
Felip,
M.
Heuvel,
T.
Ciuleanu,
F.
Badin,
N.
Ready,
Jeroen
Hiltermann,
S.
Nair,
R.
Juergens,
S.
Peters,
E.
Minenza,
John
Wrangle,
D.
Rodríguez-Abreu,
H.
Borghaei,
G.
Blumenschein,
L.
Villaruz,
L.
Havel,
J.
Krejci,
J.
Jaime,
Han
Chang,
W.
Geese,
P.
Bhagavatheeswaran,
Allen
Chen,
M.
Socinski
(2017)
First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer
The New England Journal of Medicine, 376
-
A.
Liberati,
D.
Altman,
J.
Tetzlaff,
C.
Mulrow,
P.
Gøtzsche,
J.
Ioannidis,
M.
Clarke,
P.
Devereaux,
J.
Kleijnen,
D.
Moher
(2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
The BMJ, 339
-
J.
Schachter,
A.
Ribas,
G.
Long,
A.
Arance,
J.
Grob,
L.
Mortier,
A.
Daud,
M.
Carlino,
C.
McNeil,
M.
Lotem,
J.
Larkin,
P.
Lorigan,
B.
Neyns,
C.
Blank,
T.
Petrella,
O.
Hamid,
Honghong
Zhou,
S.
Ebbinghaus,
N.
Ibrahim,
C.
Robert
(2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
The Lancet, 390
-
R.
Motzer,
B.
Escudier,
D.
McDermott,
S.
George,
H.
Hammers,
S.
Srinivas,
S.
Tykodi,
J.
Sosman,
G.
Procopio,
E.
Plimack,
D.
Castellano,
T.
Choueiri,
H.
Gurney,
F.
Donskov,
P.
Bono,
J.
Wagstaff,
T.
Gauler,
Takeshi
Ueda,
Yoshihiko
Tomita,
F.
Schutz,
C.
Kollmannsberger,
J.
Larkin,
A.
Ravaud,
J.
Simon,
Li-an
Xu,
I.
Waxman,
P.
Sharma
(2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
The New England journal of medicine, 373 19
-
(2018)
Immunerelated adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and metaanalysis
-
K.
Shitara,
M.
Özgüroğlu,
Y.
Bang,
M.
Bartolomeo,
M.
Mandalà,
M.
Ryu,
L.
Fornaro,
T.
Olesiński,
C.
Caglevic,
H.
Chung,
K.
Muro,
E.
Goekkurt,
W.
Mansoor,
R.
McDermott,
E.
Shacham-Shmueli,
Xinqun
Chen,
C.
Mayo,
S.
Kang,
A.
Ohtsu,
C.
Fuchs,
G.
Lerzo,
J.
O'Connor,
G.
Mendez,
J.
Lynam,
N.
Tebbutt,
M.
Wong,
A.
Strickland,
C.
Karapetis,
D.
Goldstein,
P.
Vasey,
J.
Laethem,
E.
Cutsem,
S.
Berry,
M.
Vincent,
Bettina
Muller,
F.
Rey,
A.
Zambrano,
J.
Guerra,
M.
Krogh,
L.
Baeksgaard,
M.
Yilmaz,
A.
Elme,
Andrus
Magi,
P.
Auvinen,
T.
Alanko,
M.
Moehler,
V.
Kunzmann,
T.
Seufferlein,
P.
Thuss-Patience,
T.
Hoehler,
G.
Haag,
S.
Al-Batran,
H.
Castro,
Karla
Lopez,
Mynor
Vasquez,
Mario
Sandoval,
K.
Lam,
S.
Cuffe,
C.
Kelly,
R.
Geva,
A.
Hubert,
A.
Beny,
B.
Brenner,
Aprile
Giuseppe,
A.
Falcone,
E.
Maiello,
R.
Passalacqua,
V.
Montesarchio,
H.
Hara,
K.
Chin,
T.
Nishina,
Y.
Komatsu,
N.
Machida,
S.
Hironaka,
T.
Satoh,
T.
Tamura,
Naotaoshi
Sugimoto,
Haruhiko
Cho,
Yashushi
Omuro,
Ken
Kato,
M.
Goto,
I.
Hyodo,
Kazuhiro
Yoshida,
H.
Baba,
T.
Esaki,
J.
Furuse,
Wan
Mohammed,
Carlos
Hernandez,
Juan
Garcia,
Adriana
Andrade,
Katriona
Clarke,
G.
Hjortland,
N.
Glenjen,
T.
Kubiatowski,
J.
Jacek,
M.
Wojtukiewicz,
S.
Lazarev,
Yuri
Lancukhay,
Sergey
Afanasayev,
V.
Moiseyenko,
V.
Kostorov,
S.
Protsenko,
V.
Shirinkin,
D.
Sakaeva,
N.
Fadeeva,
W.
Yong,
C.
Ng,
B.
Robertson,
B.
Rapaport,
G.
Cohen,
L.
Dreosti,
P.
Ruff,
C.
Jacobs,
G.
Landers,
W.
Szpak,
S.
Roh,
Jeeyun
Lee,
Yeul-Hong
Kim,
H.
Chung,
María
Maqueda,
F.
Muñoz,
Andres
Aguilar,
E.
Aguilar,
P.
Alfonso,
F.
Rivera,
Jaime
Batle,
R.
Cid,
K.
Yeh,
Jen‐Shi
Chen,
Y.
Chao,
C.
Yen,
O.
Kara,
Ş.
Yalçın,
D.
Hochhauser,
I.
Chau,
A.
Benson,
V.
Shankaran,
W.
Shaib,
P.
Philip,
V.
Sharma,
R.
Siegel,
Weijing
Sun,
Z.
Wainberg,
B.
George,
A.
Bullock,
S.
Myrick,
Josephine
Faruol,
Richard
Siegel,
T.
Larson,
C.
Becerra,
Suresh
Ratnam,
D.
Richards,
Stephen
Riche
(2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
The Lancet, 392
-
C.
Begg,
Madhuchhanda
Mazumdar
(1994)
Operating characteristics of a rank correlation test for publication bias.
Biometrics, 50 4
-
T.
Hoffmann,
C.
Mar
(2015)
Patients' expectations of the benefits and harms of treatments, screening, and tests: a systematic review.
JAMA internal medicine, 175 2
-
J.
Wolchok,
V.
Chiarion-Sileni,
R.
Gonzalez,
P.
Rutkowski,
J.
Grob,
L.
Cowey,
C.
Lao,
J.
Wagstaff,
D.
Schadendorf,
P.
Ferrucci,
M.
Smylie,
R.
Dummer,
A.
Hill,
D.
Hogg,
J.
Haanen,
M.
Carlino,
O.
Bechter,
M.
Maio,
I.
Márquez-Rodas,
M.
Guidoboni,
G.
McArthur,
C.
Lebbé,
P.
Ascierto,
G.
Long,
J.
Cebon,
J.
Sosman,
M.
Postow,
M.
Callahan,
D.
Walker,
L.
Rollin,
R.
Bhore,
S.
Hodi,
J.
Larkin
(2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
The New England Journal of Medicine, 377
-
Yoon-Koo
Kang,
N.
Boku,
T.
Satoh,
M.
Ryu,
Y.
Chao,
Ken
Kato,
H.
Chung,
Jen‐Shi
Chen,
K.
Muro,
W.
Kang,
K.
Yeh,
T.
Yoshikawa,
S.
Oh,
L.
Bai,
T.
Tamura,
Keun-Wook
Lee,
Y.
Hamamoto,
Jong
Kim,
K.
Chin,
D.
Oh,
K.
Minashi,
J.
Cho,
M.
Tsuda,
Li‐Tzong
Chen
(2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet, 390
-
Cheng
Xu,
Yupei
Chen,
Xiao-jing
Du,
Jin-Qi
Liu,
Cheng‐long
Huang,
Lei
Chen,
G.
Zhou,
Wen-Fei
Li,
Y.
Mao,
Chiun
Hsu,
Qing
Liu,
A.
Lin,
L.
Tang,
Ying
Sun,
Jun
Ma
(2018)
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
The BMJ, 363
-
Jeffrey
Weber,
S.
D’Angelo,
D.
Minor,
F.
Hodi,
R.
Gutzmer,
B.
Neyns,
C.
Hoeller,
N.
Khushalani,
Wilson
Miller,
C.
Lao,
G.
Linette,
L.
Thomas,
P.
Lorigan,
K.
Grossmann,
Jessica
Hassel,
M.
Maio,
M.
Sznol,
P.
Ascierto,
P.
Mohr,
B.
Chmielowski,
A.
Bryce,
I.
Svane,
J.
Grob,
Angela
Krackhardt,
C.
Horak,
A.
Lambert,
Arvin
Yang,
J.
Larkin
(2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
The Lancet. Oncology, 16 4
-
Xian
Shen,
Bin
Zhao
(2018)
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
The BMJ, 362
-
L.
Fehrenbacher,
A.
Spira,
M.
Ballinger,
M.
Kowanetz,
J.
Vansteenkiste,
J.
Mazières,
Keunchil
Park,
David
Smith,
A.
Artal-Cortes,
C.
Lewanski,
F.
Braiteh,
D.
Waterkamp,
P.
He,
W.
Zou,
Daniel
Chen,
J.
Yi,
A.
Sandler,
A.
Rittmeyer
(2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
The Lancet, 387
-
(2019)
inhibitors for metastatic melanoma
-
K.
Wester,
A.
Jönsson,
O.
Spigset,
H.
Druid,
S.
Hägg
(2008)
Incidence of fatal adverse drug reactions: a population based study.
British journal of clinical pharmacology, 65 4
-
A.
Ribas,
I.
Puzanov,
R.
Dummer,
D.
Schadendorf,
O.
Hamid,
C.
Robert,
F.
Hodi,
J.
Schachter,
A.
Pavlick,
Karl
Lewis,
L.
Cranmer,
Christian
Blank,
S.
O'Day,
P.
Ascierto,
April
Salama,
K.
Margolin,
C.
Loquai,
Thomas
Eigentler,
T.
Gangadhar,
M.
Carlino,
S.
Agarwala,
S.
Moschos,
J.
Sosman,
S.
Goldinger,
R.
Shapira-Frommer,
R.
Gonzalez,
J.
Kirkwood,
J.
Wolchok,
A.
Eggermont,
Xiaoyun
Li,
W.
Zhou,
Adriane
Zernhelt,
Joy
Lis,
S.
Ebbinghaus,
S.
Kang,
A.
Daud
(2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
The Lancet. Oncology, 16 8
-
S.
Baxi,
Annie
Yang,
R.
Gennarelli,
N.
Khan,
Ziwei
Wang,
Lindsay
Boyce,
D.
Korenstein
(2018)
Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
The BMJ, 360
-
M.
Reck,
D.
Rodríguez-Abreu,
A.
Robinson,
R.
Hui,
T.
Csőszi,
A.
Fülöp,
M.
Gottfried,
N.
Peled,
A.
Tafreshi,
S.
Cuffe,
M.
O'Brien,
Suman
Rao,
K.
Hotta,
M.
Leiby,
G.
Lubiniecki,
Shentu
Yue,
Reshma
Rangwala,
J.
Brahmer
(2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
The New England journal of medicine, 375 19
-
A.
Rittmeyer,
F.
Barlesi,
D.
Waterkamp,
Keunchil
Park,
F.
Ciardiello,
J.
Pawel,
S.
Gadgeel,
T.
Hida,
D.
Kowalski,
M.
Dols,
D.
Cortinovis,
J.
Leach,
J.
Polikoff,
C.
Barrios,
F.
Kabbinavar,
O.
Frontera,
F.
Marinis,
H.
Turna,
Jong-Seok
Lee,
M.
Ballinger,
M.
Kowanetz,
P.
He,
Daniel
Chen,
A.
Sandler,
D.
Gandara
(2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
The Lancet, 389
-
Bin
Zhao,
Hong
Zhao,
Jiaxin
Zhao
(2018)
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
Journal for Immunotherapy of Cancer, 6
-
A.
Kythreotou,
A.
Siddique,
F.
Mauri,
M.
Bower,
D.
Pinato
(2017)
PD-L1
Journal of Clinical Pathology, 71
-
Daniel
Wang,
Fei
Ye,
Shilin
Zhao,
Douglas
Johnson
(2017)
Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis
OncoImmunology, 6
-
S.
Zhang,
F.
Liang,
Wenfeng
Li,
Qing
Wang
(2017)
Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis.
European journal of cancer, 83
-
O.
Abdel-Rahman,
D.
Helbling,
Jan
Schmidt,
U.
Petrausch,
A.
Giryes,
A.
Mehrabi,
O.
Schöb,
M.
Mannhart,
H.
Oweira
(2017)
Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Clinical oncology (Royal College of Radiologists (Great Britain)), 29 4
-
H.
Borghaei,
L.
Paz-Ares,
L.
Horn,
D.
Spigel,
M.
Steins,
N.
Ready,
L.
Chow,
E.
Vokes,
E.
Felip,
E.
Holgado,
F.
Barlesi,
M.
Kohlhäufl,
O.
Arrieta,
M.
Burgio,
J.
Fayette,
H.
Léna,
E.
Poddubskaya,
D.
Gerber,
S.
Gettinger,
C.
Rudin,
N.
Rizvi,
L.
Crinò,
G.
Blumenschein,
S.
Antonia,
C.
Dorange,
C.
Harbison,
F.
Finckenstein,
J.
Brahmer
(2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
The New England journal of medicine, 373 17
-
J.
Higgins,
S.
Thompson,
J.
Deeks,
D.
Altman
(2003)
Measuring inconsistency in meta-analyses
BMJ : British Medical Journal, 327
-
Hongli
Zhao,
Liyuan
Guo,
Hong
Zhao,
Jiaxin
Zhao,
H.
Weng,
Bin
Zhao
(2014)
CXCR4 over-expression and survival in cancer: A system review and meta-analysis
Oncotarget, 6